

1 **Short report**

2 **Title:** Efficacy of N-163 strain of *Aureobasidium pullulans*-produced beta-glucan in
3 improving muscle strength and function in patients with Duchenne muscular dystrophy;
4 Results of a 6-month non-randomised open-label linear clinical trial

5 **Running Title:** N-163 beta glucan in DMD improves muscle function

6 **Authors:**

7 Kadalraja Raghavan¹ (drkraghavan@nichimail.jp)

8 Thanasekar Sivakumar¹ (siva.ctg@gmail.com)

9 Sudhakar S Bharatidasan² (drsudhakar77@gmail.com)

10 Subramaniam Srinivasan³ (masala76@gmail.com)

11 Vidyasagar Devaprasad Dedeepiya³ (drddp@nichimail.jp)

12 Nobunao Ikewaki^{4,5} (nikewaki@phoenix.ac.jp)

13 Rajappa Senthilkumar^{6,7} (rsk@nichimail.jp)

14 Senthilkumar Preethy⁶ (drspp@nichimail.jp)

15 Samuel JK Abraham^{3,7,8,9,10} (drsam@nichimail.jp)

16 **Affiliations:**

17 1. Dept of Paediatric Neurology, Jesuit Antonyraj memorial Inter-disciplinary Centre for
18 Advanced Recovery and Education (JAICARE), Madurai, India

19 2. Department of Anesthesia, Thunder Bay Regional Health Sciences Centre, Thunder
20 Bay, Ontario, Canada

21

- 22 3. Mary-Yoshio Translational Hexagon (MYTH), Nichi-In Centre for Regenerative
23 Medicine (NCRM), Chennai, India.
- 24 4. Dept. of Medical Life Science, Kyushu University of Health and Welfare, Japan
- 25 5. Institute of Immunology, Junsei Educational Institute, Nobeoka, Miyazaki, Japan
- 26 6. Fujio-Eiji Academic Terrain (FEAT), Nichi-In Centre for Regenerative Medicine
27 (NCRM), Chennai, India.
- 28 7. Antony- Xavier Interdisciplinary Scholastics (AXIS), GN Corporation Co. Ltd., Kofu,
29 Japan.
- 30 8. Centre for Advancing Clinical Research (CACR), University of Yamanashi - School
31 of Medicine, Chuo, Japan.
- 32 9. R & D, Sophy Inc., Japan
- 33 10. Levy-Jurgen Transdisciplinary Exploratory (LJTE), Global Niche Corp., Wilmington,
34 DE, USA

35
36

37 **Corresponding author information:**

38 Dr. Samuel JK Abraham,

39 II Department of Surgery & CACR,

40 University of Yamanashi, Faculty of Medicine

41 Address for correspondence: 3-8, Wakamatsu, Kofu, 400-0866, Yamanashi, Japan

42 Email id- drsam@nichimail.jp; Alternate email id: drsp@nichimail.jp

43 Fax: +81-55-235-7569

44

45 **Declarations:**

46 *Ethics approval and consent to participate*

47 The study was registered in Clinical trials registry of India, CTRI/2022/05/042905 and
48 approved by the ethics committee of Saravana Multispeciality Hospital-Institutional Ethics
49 Committee, India

50 *Consent for publication*

51 Not applicable

52 *Availability of data and material*

53 All data generated or analysed during this study are included in the article itself.

54 *Funding*

55 No external funding was received for the study

Competing

interests

Author Samuel Abraham is a shareholder in GN Corporation, Japan which holds shares of Sophy Inc., Japan., the manufacturers of novel beta glucans using different strains of *Aureobasidium pullulans*; a board member in both the companies and also an applicant to several patents of relevance to these beta glucans.

56 *Authors' contributions*

57 KR, NI and SA. contributed to conception and design of the study. KR and RS helped in data
58 collection and analysis. SA and SP drafted the manuscript. VD, SS and SB performed critical
59 revision of the manuscript. All authors read and approved the final manuscript.

60 *Acknowledgements*

61 The authors thank

62 1. The Government of Japan and the Prefectural Government of Yamanashi for a special
63 loan and M/s Yamanashi Chuo Bank for processing the transactions.

64 2. Ms. Sunitha, Mr. Vincent and the staff of JAICARE and Sarvee Integra, Dr.
65 Ragaroobine, Mr. Rajmohan from Nichi-In Centre for Regenerative Medicine (NCRM) for
66 their assistance during the clinical study and data collection of the manuscript.

67 3. Fr. Francis Xavier, Rector, Loyola College, Chennai, Fr. Vargheesh Antony and Fr.
68 Marianathan of JAICARE for their support during the clinical study.

69 4. Ms. Misa Takamoto, Mr. Masato Onaka, Mr. Yasushi Onaka of Sophy Inc, Kochi,
70 Japan for necessary technical support.

71 5. Ms. Yoshiko Amikura and staff of GN Corporation, Japan for their liaison assistance
72 with the conduct of the study.

73 6. Loyola-ICAM College of Engineering and Technology (LICET) for their support to
74 our research work.

75

76

77

78

79

80

81

82

83 **Abstract:**

84 Duchenne muscular dystrophy (DMD) is a debilitating genetic disease that causes gradual
85 muscle weakening and early mortality. After a 45-day clinical pilot study and a pre-clinical
86 study in mdx mice demonstrating safety and efficacy, and anti-fibrotic and anti-inflammatory
87 effects, respectively, of an *Aureobasidium pullulans* N-163 strain-produced B-1,3–1,6-
88 glucan. We conducted this linear six-month clinical study to assess its efficacy. Twelve
89 ambulatory and 12 non-ambulatory individuals with DMD were included; all received the N-
90 163 strain of *A.pullulans* produced beta-glucan dietary supplement orally in addition to the
91 standard treatment regimen, which included steroids. The Medical Research Council muscle
92 score improved in 11 patients in the ambulatory group and in 8 patients in the non-
93 ambulatory group. The six-minute walk test distance improved in nine patients, with a 29.5-
94 meter average improvement. The North Star Ambulatory Assessment improved by 1 unit in
95 three patients. This safe beta-glucan food supplement improved muscle function within 6
96 months. A comprehensive, multi-centric clinical research should be conducted for unravelling
97 its potential as a disease- modifying drug adjuvant in DMD.

98

99 **Keywords:** Duchenne muscular dystrophy; N-163; beta glucan; disease modifying agent; 6-
100 minute walk test

101 **Introduction:**

102 Duchenne muscular dystrophy (DMD) is a lethal X-linked recessive disease, whose
103 prevalence varies between 1 in 3600 and 1 in 9300 male infants globally.¹ Loss-of-function
104 mutations in the DMD gene prevent the production of functional dystrophin protein in
105 patients with DMD, which causes progressive skeletal muscle weakening and degeneration,
106 heart dysfunction, respiratory failure, and ultimately premature death.^{1,2} The two treatment
107 approaches for DMD are as follows: the first is dystrophin-targeted therapy, and the
108 alternative is to focus on the pathological alterations that occur downstream. Gene, cell, and
109 protein replacement therapies are examples of treatments that target dystrophin. However,
110 dystrophin-targeted therapy can only slow the course of the disease and cannot restore the
111 function of defective muscle tissues. Second, owing to the body's widespread distribution of
112 muscle tissue, dystrophin-targeted medicines have difficulty reaching all muscle tissues.³
113 Targeting secondary downstream pathological mechanisms is another therapeutic approach.
114 Multiple pathogenic processes, such as fibrosis, inflammation, loss of calcium homeostasis,
115 oxidative stress, ischaemia, and muscular atrophy, are triggered by downstream pathological
116 mechanisms.³ Different approaches that target fibrosis, inflammation, ischaemia, etc., are
117 available, although a wholesome approach to DMD that aims both at dystrophin replacement
118 as well as addressing downstream pathological mechanisms is necessary.

119 Previously, we have reported on a 1-3,1-6 beta-glucan from the N-163 strain of the black
120 yeast *Aureobasidium pullulans* that helped decrease interleukin (IL)-6, tumour growth factor
121 (TGF)- β , and IL-13 and increase dystrophin levels along with improvement of muscle
122 strength in patients with DMD in a clinical study performed in 28 patients with DMD for a
123 duration of 45 days.⁴ In the same study, we reported the beneficial constitution of the gut
124 microbiome with an increase in butyrate-producing species such as *Roseburia* and
125 *Faecalibacterium prausnitzii*, apart from a decrease in harmful bacteria associated with

126 inflammation such as enterobacteria and *Alistipes*.⁵ We also conducted a pre-clinical study of
127 this N-163 beta-glucan in an mdx mice model, which revealed a significant decrease in
128 inflammation score and fibrosis as well as levels of plasma alanine transaminase, aspartate
129 aminotransferase, lactate dehydrogenase, IL-13, and haptoglobin; increased anti-
130 inflammatory TGF- β levels; and balanced regulation of the quantity of centrally nucleated
131 fibres indicative of muscle regeneration.⁶ In a pre-clinical study of mdx mice, we also
132 reported muscle regeneration and maturation by MYH3 and CD44 expression.⁷ In the present
133 study, we evaluated the effects of N-163 beta-glucan for 6 months in patients with DMD.

134 **Materials and methods:**

135 This trial was an investigator-initiated, single-centre, randomised, open-label, prospective,
136 linear, single-arm clinical study of patients with DMD. This study was conducted over a
137 period of 180 days.

138 The intervention was consumption of one sachet of N-163 beta-glucan (Commercial name:
139 Neu-REFIX) once daily along with conventional treatment comprising routine physiotherapy
140 for joint mobility along with medications, viz., T. calcium and vitamin D 1000 with or
141 without deflazacort (steroid) 6–24 mg.

142 ***Inclusion criteria:***

143 This study included male patients with a molecular diagnosis of DMD aged 3–30 years who
144 were willing to participate in the study with written informed consent.

145 ***Exclusion criteria:***

146 Patients with a previous (within the past 1 month) or concomitant participation in any other
147 therapeutic trial; a known or suspected malignancy; any other chronic disease, or clinically

148 relevant limitation of renal, liver, or heart function according to the discretion of the
149 investigator were excluded from the study.

150 ***Investigations:***

151 A background survey was conducted to obtain data on sex, date of birth, age, habits, current
152 medical history, medication, treatment, allergies (to drugs and food), regular use of food for
153 specified health uses, functional foods, health foods, intake of foods rich in beta-glucan and
154 foods containing beta-glucan, and intake of immunity-boosting foods. Medical history and
155 physical measurements were taken, including height, weight, body mass index, and
156 temperature. The following tests were performed at baseline and at the end of the study (6
157 months).

- 158 1. Physiological examination included assessing the systolic blood pressure, diastolic
159 blood pressure, and pulse rate.
- 160 2. Electrocardiogram (ECG).
- 161 3. The Medical Research Council (MRC) Scale was used to measure muscle strength.
- 162 4. six-minute walk test (6MWT) and North Star Ambulatory Assessment (NSAA)

163 The participants were contacted every week for drug compliance and the recording of adverse
164 effects, if any.

165 At 3 and 6 months, a physiological examination was performed to assess systolic blood
166 pressure, diastolic blood pressure, and pulse rate.

167 ***Statistical analysis:***

168 Microsoft Office Excel statistics package and the software Origin 2021b were used for
169 statistical analysis. Statistical significance was set at $p < 0.05$, and multiple comparisons or
170 multiple outcomes were not corrected.

171 **Results:**

172 Altogether, 27 patients were screened, of whom 24 were included in the study. The mean \pm
173 standard deviation of age for the total study population was 11.33 ± 4.57 years (range, 5–26
174 years).

175 No adverse events were observed. No clinically significant changes from baseline data were
176 observed on physical examination or in vital signs—temperature, blood pressure, oxygen
177 saturation, pulse rate, or ECG (data not shown).

178 The mean NSAA score at pre-intervention (21.41 ± 11.81) and post-intervention ($21.58 \pm$
179 11.87) did not indicate any significant change. The NSAA score improved by 1 unit in three
180 patients and decreased by 1 unit in one patient. In the remaining patients, no change was
181 identified (Figure 1). In the ambulatory group ($n=12$), the MRC score improved in 11
182 patients, with an average improvement of 7.09%, while it increased by 9.27% in 8 of the 12
183 non-ambulatory patients and decreased in 2 cases (Figure 2). The 6MWT distance improved
184 in 9 patients, with a 29.5-metre average improvement (Figure 3).

185 **Discussion:**

186 The goal of DMD treatment is to correct genetic defects and restore muscle function apart
187 from re-establishing normal levels of dystrophin.¹⁻³ Despite some approaches being in
188 clinical trials, gene correction therapies such as exon-skipping therapies are available only for
189 a select group of patients with specific exon deletions. Although supportive treatments aim to
190 halt or delay the disease progression, they do not significantly contribute to muscle
191 regeneration and the restoration of muscle function, apart from the associated side effects.
192 Even in long-term studies, only in terms of delaying the disease progression, positive
193 outcome was reported without any improvement of muscle strength or function after the
194 intervention compared to the baseline data in the treatment arm⁸. One of the reasons for the

195 lack of adequate muscle regeneration is inflammation.¹⁻³ Since we have earlier proven the
196 decrease in inflammation through biomarker levels in clinical and pre-clinical studies,⁴⁻⁶
197 restoration of gut microbiome⁶, and muscle regeneration after consumption of N-163 strain of
198 *Aureobasidium pullulans* produced beta-glucan evident from increased MYH3 expression
199 and proper muscle maturation by increased CD44 hyaluronan expression in an mdx mice
200 model,⁷ which could be attributed to the clinical improvement in muscle strength and
201 function in the present study.

202 In our present study of only six months, the 6MWT distance improved in 9 patients, with a
203 29.5-metre average improvement. Although the NSAA scores did not indicate any significant
204 differences pre- and post-intervention, the improvement in MRC grading in 91.6% of the
205 participants, apart from improvement in the 6MWT indicates the significance of this N-163-
206 produced beta-glucan approach in terms of muscle function improvement, which is not
207 commonly observed with conventional or even other recent therapeutic approaches.

208 The limitations of this study are its smaller sample size and heterogeneity of the standard
209 treatment regimens followed and a duration of six-months. Nevertheless, the safety and
210 muscle function improvement efficacy of this N-163-produced beta-glucan food supplement
211 without adverse reactions can be considered an indispensable addition to disease-modifying
212 treatments for DMD and other dystrophies, such as limb-girdle muscular dystrophy.

213 **Conclusion:**

214 This safe N-163 strain of *Aureobasidium pullulans* produced beta-glucan food supplement is
215 a promising disease-modifying pharmacological adjuvant in DMD, as it improved MRC in
216 91.6% of the patients, with modest improvements in 6MWT and NSAA score after 6 months.

217 In the future, a comprehensive, multi-centric clinical study should be conducted to unravel

218 the potentials of this orally consumable, safe, and allergen-free food supplement as a drug
219 adjuvant in delaying the progression of DMD and other dystrophies.

220

221

222

223 **Abbreviations:**

224 DMD: Duchenne muscular dystrophy

225 6MWT: Six-minute walk test

226 NSAA: North Star Ambulatory Assessment

227 MRC: Medical Research Council

228

229

230 **References:**

231 1. Liew WK, Kang PB. Recent developments in the treatment of Duchenne muscular
232 dystrophy and spinal muscular atrophy. *Ther Adv Neurol Disord*. 2013 May;6(3):147-
233 60.

234 2. Clemens PR, Rao VK, Connolly AM, Harper AD, Mah JK, McDonald CM, Smith
235 EC, Zaidman CM, Nakagawa T; CINRG DNHS Investigators; Hoffman EP. Long-
236 Term Functional Efficacy and Safety of Viltolarsen in Patients with Duchenne
237 Muscular Dystrophy. *J Neuromuscul Dis*. 2022;9(4):493-501.

- 238 3. Yao S, Chen Z, Yu Y, Zhang N, Jiang H, Zhang G, Zhang Z, Zhang B. Current
239 Pharmacological Strategies for Duchenne Muscular Dystrophy. *Front Cell Dev Biol.*
240 2021 Aug 19;9:689533
- 241 4. Raghavan K, Dedeepiya VD, Srinivasan S, Pushkala S, Subramanian S, Ikewaki N,
242 Iwasaki M, Senthilkumar R, Preethy S, Abraham S. Disease-modifying immune-
243 modulatory effects of the N-163 strain of *Aureobasidium pullulans*-produced 1,3-1,6
244 Beta glucans in young boys with Duchenne muscular dystrophy: Results of an open-
245 label, prospective, randomized, comparative clinical study. *medRxiv*
246 2021.12.13.21267706; doi: 10.1101/2021.12.13.21267706
- 247 5. Raghavan K, Dedeepiya VD, Yamamoto N, Ikewaki N, Iwasaki M, Dinassing A,
248 Senthilkumar R, Preethy S, Abraham SJK. Randomised trial of *Aureobasidium*
249 *pullulans*-produced beta 1,3-1,6-glucans in patients with Duchenne muscular
250 dystrophy: Favourable changes in gut microbiota and clinical outcomes indicating
251 their potential in epigenetic manipulation. *medRxiv* 2022.12.09.22283273; doi:
252 10.1101/2022.12.09.22283273
- 253 6. Preethy S, Aoki Y, Minegishi K, Senthilkumar R, Abraham S. Resolution of fibrosis
254 in mdx dystrophic mouse after oral consumption of N-163 strain of *Aureobasidium*
255 *pullulans* produced biological response modifier β -glucan (BRMG). *bioRxiv*
256 2022.11.17.516628; doi: 10.1101/2022.11.17.516628
- 257 7. Abraham S, Sakamoto S, Higuchi T, Srinivasan S, Dedeepiya VD, Ikewaki N,
258 Iwasaki M, Rajmohan M, Senthilkumar R, Preethy S. Enhanced muscle regeneration
259 in MDX Duchenne muscular dystrophy-mice, proven by CD44 & MYH3, on
260 consumption of *A. Pullulans* produced Neu REFIX β -Glucan. MDA Conference 2023,
261 Dallas, Texas, USA.

262 8. Servais L, Mercuri E, Straub V, Guglieri M, Seferian AM, Scoto M, Leone D, Koenig
263 E, Khan N, Dugar A, Wang X, Han B, Wang D, Muntoni F; SKIP-NMD Study
264 Group. Long-Term Safety and Efficacy Data of Golodirsen in Ambulatory Patients
265 with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A First-in-
266 human, Multicenter, Two-Part, Open-Label, Phase 1/2 Trial. *Nucleic Acid Ther.* 2022
267 Feb;32(1):29-39.

268

269

270

271

272

273

274

275

276

277

278


279

280

281

282

283 **Figures**



285 **Figure 1: North Star Ambulatory Assessment Score pre- and post-intervention of N-163**
286 **beta-glucan in patients with Duchenne muscular dystrophy.**

287

288

289

290

291

292

293

294


295

296

297

298

299



300

301

302

Figure 2: Medical Research Council grading pre- and post-intervention of N-163 beta-glucan in patients with Duchenne muscular dystrophy.

303

304

305

306

307

308

309

310

311

312

313

314

315

316


317

318

319

320

321



322

323 **Figure 3: Six-minute walk test score pre- and post-intervention of N-163 beta-glucan in**

324 **patients with Duchenne muscular dystrophy.**

325